Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 1085-1090

  Mdluli, Khisimuzi ^b   Sherman, David R ^b   Hickey, Mark J ^b   Kreiswirth, Barry N ^b   Morris, Sheldon ^b   Stover, C Kendall ^b   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; GENE FUSION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TUBERCULOSIS;

EID: 0029859098     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.1085     Document Type: Article

References (25)

1. Takayama K, Davidson LA. Isonicotinic acid hydrazide. In: Hahn FE, ed. Antibiotics. Vol. I. Mechanism of action of antibacterial agents. Berlin: Springer Verlag, 1979:98-119.
2. Zhang Y, Young DB. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. Trends Microbiol 1993;1:109-13.
3. Rosner JL. Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother 1993;37:2251-3.
4. Winder FG. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In: Ratledge C, Stanford JL, eds. The biology of the mycobacteria. Vol. 1. San Diego: Academic Press, 1982:353-438.
5. Zhang Y, Heym B, Alien B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
6. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994;116:7425-6.
7. Morris S, Bai GH, Suffys P, Portillo-Gomez L, Fairchock M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995;171:954-60.
8. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embdan JDA. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
9. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1972;2:29-35.
10. Takayama, K, Schnoes HK, Armstrong EL, Boyle RW. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 1975;16:308-17.
11. Davidson LA, Takayama K. Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1979;16:104-5.
12. Banerjee A, Dubnau E, Quemard A, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
13. Quemard A, Sacchettini JC, Dessen A, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995;34:8235-41.
14. Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Saccettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995;267:1638-41.
15. Johnsson K, King DS, Schultz PG. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 1995;117:5009-10.
16. Hickey MJ, Arain TM, Shawar RM, et al. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 1996;40:400-7.
17. Hawkins JE. Drug susceptibility testing. In: Kubica GP, Wayne LG, eds. The mycobacteria: a sourcebook. Part A. New York, NY: Marcel Dekker, 1984:177-93.
18. Kapur V, Li LL, Harnrick MR, et al. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
19. Stover CK, Bansal GP, Hansen MS, et al. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate lyme disease vaccine. J Exp Med 1993;178:197-209.
20. Quemard A, Dessen A, Sugantino M, Jacobs WR Jr, Sacchettini JC, Blanchard JS. Binding of catalase-peroxidase-activated isoniazid to wild-type and mutant Mycobacterium tuberculosis enoyl-ACP reductases. J Am Chem Soc 1996;118:1561-2.
21. Zhang Y, Garbe T, Young DB. Transformation with kalG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1993;8:521-4.
22. Wilson TM, de Lisle GW, Collins D. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995;15:1009-15.
23. Heym B, Honore N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994;344:293-8.
24. Ristow M, Mohlig M, Rifai M, Schatz H, Feldman K, Pfeiffer A. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 1995;346:502-3.
25. Sherman DR, Mdluli KM, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996;272:1641-3.